Hepatitis Vaccines

Sharon Frey, MD
Chair, Hepatitis Vaccines Work Group

Advisory Committee on Immunization Practices
February 27, 2020
ACIP Hepatitis WG Term of Reference

- Hepatitis B
  - Update the recommendations for HepB vaccination among U.S. adults
Current Recommendations Published Since 2008


Work Group Considerations

- **September 2019 - November 2019**
  - Meetings focused on:
    - Developing the PICO question
    - Estimating denominators of risk groups

- **January 2020**
  - Presentation of interim results of post-marketing surveillance study, given by principal investigator (Kaiser Permanent Southern California)

- **Prepare for discussion, Spring 2020**
  - Discussion of the cost-effectiveness analysis (CEA)
  - CEA is currently under ACIP technical review (external to the work group)
Policy question under discussion: Should a routine universal HepB-vaccination strategy (2-dose and 3-dose schedules) be utilized vs. the current risk based vaccination strategy (2-dose and 3-dose) for adults?

<table>
<thead>
<tr>
<th>Population</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Universal vaccination strategy</td>
</tr>
<tr>
<td>Comparison</td>
<td>Current risk based vaccination strategy</td>
</tr>
</tbody>
</table>
| Outcomes of interest | ▪ Mortality  
▪ Morbidity  
▪ Incidence  
▪ Vaccine uptake  
▪ Seroprotection  
▪ Adverse events (mild and serious) |
Next Steps

- Continue deliberations on updates to adult hepatitis B vaccination
  - Complete the CEA review process and present the CEA to the Work Group
  - Discuss the final results of the post-marketing surveillance study for HEPLISAV-B, when available
  - Initiate the GRADE and Evaluation to Recommendation framework (EtR) for universal adult hepatitis B vaccination
Hepatitis Work Group Members

ACIP Members
Sharon Frey (Chair)
José Romero

Ex Officio Member
Marian Major (FDA)
Darcie Everett (FDA)

Lead
Mark Weng
(CDC/Division of Viral Hepatitis)

Liaison Representatives
Elizabeth Barnett (AAP)
Susan Even (ACHA)
Christine Finley (AIM)
Brenna Hughes (ACOG)
Susan Lett (CSTE)
Pamela Rockwell (AAFP)
David Weber (SHEA)
Matthew Zahn (NACCHO)

Consultants
Sharon Balter (LA-DPH)
Robert Frenck (CCHMC)
Kathleen Harriman (CDPH)
Brian McMahon (ANTHC)
Kelly Moore (VUSM)
David Nace (AMDA)
Jennifer Rosen (NYC-DOH)
Ann Thomas (OR-DHS/OHA)
Jennifer Zipprich (MDPH)
Acknowledgements

- NCHHSTP/Division of Viral Hepatitis
- NCIRD/Immunization Services Division
- Doug Campos-Outcalt
- Rebecca Morgan
  - GRADE and Evidence to Recommendation framework
- Food and Drug Administration

- CDC subject matter experts
  - Mona Doshani, Jeff Nemhauser
  - Penina Haber, Tina Objio
  - Aaron Harris, Priti Patel
  - Beth Hibbs, Sarah Schillie
  - Megan Hofmeister, Tom Shimabukuro
  - Andrew Kroger, Phil Spradling
  - Noele Nelson, Tureka Watson